May 15, 2026
Despite policy headwinds, health execs are surprisingly optimistic, leveraging resilience and AI to navigate tariffs and pricing reforms.
May 8, 2026
New pharma tariffs are complex. This episode details exemptions, supply chain impacts, and mitigation tactics for drugmakers, big and small.
May 4, 2026
Scaling theranostics requires seamless logistics, stakeholder trust, and improved patient access to overcome systemic bottlenecks and shortages.
April 27, 2026
Marken's Laboratory Advantage accelerates clinical trials through precision logistics, a global network, and advanced digital oversight.
April 24, 2026
Trump's UK drug deal leverages tariffs to make allies pay more for US innovation, setting a new model for global pharma pricing.
April 21, 2026
Biomarkers are revolutionizing oncology trials, enabling adaptive designs, targeted therapies, and significantly boosting success rates.
April 20, 2026
Austin Pharmaceuticals' Kinetosol technology rescues failed spray-dried formulations by overcoming solvent and heat limitations for faster development.
April 17, 2026
Roivant’s CEO argues China's biotech rise is a red herring; the real story is tech commoditization and the US's eroding talent ecosystem.
April 10, 2026
Pharma R&D spending is down across the board for 2025, but obesity drug profits fuel a massive spending surge for outliers like Eli Lilly.
April 3, 2026
Pharma leads US reshoring, fueled by pandemic lessons & govt funds. Expect a 3-5 year shift to automated, regional supply chains.
March 27, 2026
Eli Lilly's GLP-1 dominance is challenged by an HSBC downgrade, questioning market assumptions despite a promising drug pipeline.
March 23, 2026
New UK clinical trial regs are live April 2026. Sponsors must act now on labeling for IMPs & NIMPs to avoid 11th-hour trial disruptions.
March 20, 2026
Xaira Therapeutics COO Jeff Yonker on using its $1B fundraise to build a foundational AI company to solve drug development's productivity crisis.
March 13, 2026
The biopharma industry faces a growth slowdown in 2026, as numerous companies guide conservatively due to looming patent expirations.
March 6, 2026
AI and automation are making traditional R&D labs obsolete, forcing a fundamental redesign of the physical spaces where science happens.
February 23, 2026
The US sterile fill CDMO market faces a capacity crunch from acquisitions and reshoring, creating opportunities for specialized, flexible players.
February 20, 2026
Trump's tariff threats spurred a massive pharma production boom in 2025. Now, the industry faces a slowdown and supply chain realignment.
February 3, 2026
Mirum Pharmaceuticals SVP discusses the Bluejay acquisition, bolstering their rare disease pipeline with a focus on patient-centric M&A strategy.
February 2, 2026
AI enhances med comms efficiency, but human expertise remains essential for accuracy, strategic insight, and maintaining trust in scientific rigor.
January 30, 2026
Biopharma M&A rebounds in 2026 with a 'proof over promise' mindset. Expect disciplined, innovation-focused deals despite market uncertainties.
January 23, 2026
JPM26 was surprisingly quiet on mega-deals but loud on AI hype. Key themes: biotech funding woes, China's rise, and new M&A mindsets.
January 16, 2026
FDA drug approvals dipped to 46 in 2025 amid turmoil but surged in H2. European firms outpaced US counterparts, with a focus on rare diseases.
January 12, 2026
Beyond the buzzword: How integrating the patient voice transforms pharma strategy, from evidence generation to market access and communication.
December 19, 2025
Biopharma in 2026 faces a new reality shaped by US policy shifts, from federal funding cuts and FDA turmoil to global trade deals.
December 8, 2025
Walgreens leverages its massive real-world data to provide pharma with actionable insights, improving patient access, adherence, and outcomes.
